I have been off the air for a bit so a few thoughts I have re R&D, business operations and whatever else comes to mind.
Patyccc and Aruc6393 are correct re the cash into PIQ.
The 2019 Annual Report booked a receivable of $1,139,403 that PIQ was expecting. They got $1,134,662 which was $4,741 less.
If you divide $1,134,662 by 43.5% (which is the R&D cash rebate rate) you get $2,608,418 as the qualifying R&D expenditure undertaken by PIQ. The net cost to PIQ for the remainder of the qualifying R&D was $1,473,756.
The PIQ loss in the Annual Report for YEJ 2019 of $2,080,725, $1,473,756 is associated with R&D leaving $606,969 to be further analysed. $249,499 was a paper loss generated on the forced sale of shares in CPR Pharma Services that PIQ funded with shares it issued to CPR @ $0.305 approx per share. This leaves $357,470. Travel and Marketing ($227,292) and Intellectual Property maintenance expenses ($87,900) would both hopefully also represent future revenue streams and at $315,192 leaves a remainder of $42,278.
Make of that what you will but to me it looks pretty close to breakeven on Business Operations.
A very big thank you to the Australian Tax Payer, which we all are, for the R&D cash, and I hope that we can repay them with the product being made available to them soon. I am fortunately not a Type 2 Diabetic but if I was I would be doing the trip to Spain to get tested every couple of years until Promarker D testing is available here.
Finally, strength and love to OvF at this difficult time. Recently my wife's father died and the most useful website we found for understanding what to expect was a Canadian one
http://www.virtualhospice.ca/en_US/Main+Site+Navigation/Home/Topics/Topics/Final+Days/When+Death+is+Near.aspxTake care all, I always look forward to the many contributions on the PIQ Hot Copper forum.
The Rad
(20min delay)